Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Reduced plasma levels of APC or protein C (PC) are associated with an increased risk of venous thromboembolism.
|
31730817 |
2020 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
In AAs, rare coding PROC variants were not associated with VTE.
|
31680443 |
2020 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Factor V Leiden thrombophilia is characterized by a poor anticoagulant response to activated protein C (APC) and an increased risk for venous thromboembolism (VTE).
|
29294595 |
2018 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The p.R147W mutation, the c.C6152T in exon 7, causing a change in amino acid from arginine to tryptophan of the PROC gene has been reported as a common mutation in Taiwanese populations with venous thromboembolism (VTE).
|
28511552 |
2018 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These complexes as well as circulating APC were also measured in 121 patients with a history of venous thromboembolism (VTE) and 119 matched controls.
|
29448296 |
2018 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Mutations in SERPINC1 and PROC lead to deficiency or dysfunction of the two proteins, which could result in venous thromboembolism (VTE).
|
28861852 |
2018 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Seven SNPs (F5 rs6025, F2 rs1799963, ABO rs514659, FGG rs2066865, F11 rs2289252, PROC rs1799810 and KNG1 rs710446) with four SNP-SNP interactions contributed to the genetic risk score for VTE, with an AUC of 0.66 (95% CI, 0.64-0.68).
|
25472531 |
2015 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Several low-frequency genetic mutations, PROS1 p.Lys196Glu in Japanese and PROC p.Arg189Trp and p.Lys193del in Chinese, are significantly associated with increased risk for VTE, with odds ratio more than 2 through the reduced protein C anticoagulant activity.
|
24233386 |
2014 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The endogenous thrombin potential (ETP) showed a striking inter-individual variability among different FV Leiden carriers and, especially when measured in the presence of APC, correlated with VTE risk.
|
24226152 |
2014 |
Venous Thromboembolism
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The THBD 1418T allele is associated with lower soluble TM, both in plasma and in HUVEC-conditioned medium, and with an increase in functional membrane-bound TM in HUVEC, which could explain the increased activated protein C levels and the reduced VTE risk observed in individuals carrying this allele.
|
23520161 |
2013 |
Venous Thromboembolism
|
0.400 |
Therapeutic
|
phenotype |
CTD_human |
Zymogen Protein C to prevent clotting without bleeding during invasive medical procedures.
|
21445774 |
2011 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Zymogen Protein C to prevent clotting without bleeding during invasive medical procedures.
|
21445774 |
2011 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Factor V Leiden is a genetic disorder characterized by a poor anticoagulant response to activated Protein C and an increased risk for venous thromboembolism.
|
21116184 |
2011 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, high thrombin generation in the presence of APC, in women after a first event of VTE is indicative for an increased risk of a recurrence.
|
21947267 |
2011 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Among them, the factor V (FV) Leiden mutation causes a reduced ability of activated protein C to inactivate activated FV and is the most frequent genetic predisposing factor for venous thromboembolism.
|
19932655 |
2010 |
Venous Thromboembolism
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The levels of circulating activated protein C reflect in-vivo protein C activation, and a low level of activated protein C is a risk factor for venous thromboembolism.
|
19129726 |
2009 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
The complex between activated protein C (APC) and the protein C inhibitor (PCI) is a sensitive indicator of the degree of activation of blood coagulation and higher concentrations have been measured in carriers of the FV Leiden mutation who were in the recovery phase after treatment for venous thromboembolism (VTE).
|
17499343 |
2007 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Activated protein C (APC) resistance with or without factor V Leiden (FVL) is a major risk factor for venous thromboembolism.
|
16420566 |
2006 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
We investigated in case-control studies both biological effects (FVIII levels and activated protein C sensitivity ratio) and clinical associations (venous thromboembolism) of the D1241E change.
|
15735794 |
2005 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
LHGDN |
These data indicate that individuals carrying the 4600AG genotype have high sEPCR levels but do not have an increased risk of thrombosis, whereas individuals carrying the 4678CC genotype have higher APC levels and lower risk of venous thromboembolism.
|
15116250 |
2004 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Resistance to activated protein C (APC) has been demonstrated to be a risk factor for venous thromboembolism, but it is not known whether this phenotype is consistent over time.
|
15257714 |
2004 |
Venous Thromboembolism
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
These data indicate that individuals carrying the 4600AG genotype have high sEPCR levels but do not have an increased risk of thrombosis, whereas individuals carrying the 4678CC genotype have higher APC levels and lower risk of venous thromboembolism.
|
15116250 |
2004 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Activated protein C (APC) resistance is a common risk factor for venous thromboembolism (VTE) attributed to various mechanisms, including factor V Leiden (FVL) polymorphism.
|
12520697 |
2003 |
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
LHGDN |
Protein C pathway in infants and children.
|
14517747 |
2003 |
Venous Thromboembolism
|
0.400 |
AlteredExpression
|
phenotype |
LHGDN |
Protein C, antithrombin, and venous thromboembolism incidence: a prospective population-based study.
|
12067914 |
2002 |